Pattern of complications and burden of disease in patients affected by beta thalassemia major

References

• Telfer P. Update on survival in thalassaemia major. Hemoglobin 2009;33(Suppl 1):S76–S80
   PubMedGoogle Scholar
• Cappellini MD, Cohen A, Porter J, et al. Guidelines for the Management of Transfusion Dependent Thalassaemia, 3rd edn. Nicosia, Cyprus: Thalassaemia International Federation, 2014
   Google Scholar
• Borgna-Pignatti C, Cappellini M, De Stefano P, et al. Survival and complications in thalassaemia. Ann NY Acad Sci 2005;1054:40-7
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C. The life of patients with thalassaemia major. Haematologica 2010;95:345-8
   PubMed Web of Science ®Google Scholar
• Sampietro M, Tavazzi D, Martinez di Montemuros F, et al. TT virus infection in adult beta-thalassaemia major patients. Haematologica 2001;86:39-43
   PubMed Web of Science ®Google Scholar
• Di Marco V, Capra M, Angelucci E, et al.; on behalf of the Italian Society for the Study of Thalassaemia and Haemoglobinopathies and Italian Association for the Study of the Liver. Management of chronic viral hepatitis in patients with thalassaemia: recommendations from an international panel. Blood 2010:116:2875-83
   PubMed Web of Science ®Google Scholar
• Restivo Pantalone G, Renda D, Valenza F, et al. Hepatocellular carcinoma in patients with thalassaemia syndromes: clinical characteristics and outcome in a long term single centre experience. Br J Hem 2010;150:245-7
   PubMed Web of Science ®Google Scholar
• Mancuso A, Sciarrino E, Renda MC, Maggio A. A prospective study of hepatocellular carcinoma incidence in thalassaemia. Hemoglobin 2006;30:119-24
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassaemia major treated with transfusion and deferoxamine. Haematologica 2004;89:1187-93
   PubMed Web of Science ®Google Scholar
• Izadyar S, Fazeli M, Izadyar M, et al. Bone mineral density in adult patients with major thalassaemia: our experience and a brief review of the literature. Polish J Endocrinol 2012;63:264-9
   Google Scholar
• Taksande A, Prabhu S, Venkatesh S, et al. Cardiovascular aspect of beta-thalassaemia. Cardiovasc Hematol Agents Med Chem 2012;10:25-30
   PubMedGoogle Scholar
• Kremastinos DT, Aessopos A, Hahalis G, Hamodraka E, et al. β-Thalassaemia cardiomyopathy history, present considerations, and future perspectives. Circulation: Heart Failure 2010;3:451-8
   PubMed Web of Science ®Google Scholar
• Galanello R, Origa R. Beta-thalassaemia. Orphanet J Rare Dis 2010;1202:214-20
   Google Scholar
• Taher A, Isma’eel H, Mehio G, et al. Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran. Thromb Haemost 2006;96:488-91
   PubMed Web of Science ®Google Scholar
• Singer ST, Kuypers FA, Styles L, et al. Pulmonary hypertension in thalassaemia: association with platelet activation and hypercoagulable state. Am J Hematol 2006;81:670-5
   PubMed Web of Science ®Google Scholar
• Fabbri E, Forni GL, Guerrini G, Borgna-Pignatti C. Pseudoxanthoma elasticum-like syndrome and thalassaemia: an update. Dermatol Online J 2009;15:7
   PubMedGoogle Scholar
• Conte R, Ruggeri L, Gambino A, et al. The Italian multiregional thalassaemia registry: centers’ characteristics, services, and patients’ population. Hematology 2016;21:415-24
   PubMed Web of Science ®Google Scholar
• Vichinsky E, Levine L, Bhatia S, et al. Standards of Care Guidelines for Thalassaemia. Auckland: Children’s Hospital and Research Center, 2012
   Google Scholar
• European Commission. Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use. Available at: http://ec.europa.eu/health/files/eudralex/vol-1/dir_2001_83_consol_2012/dir_2001_83_cons_2012_en.pdf [Last accessed 15 December 2016]
   Google Scholar
• European Commission. Directive 2001/20/EC of the European Parliament and of the Council. Available at: http://ec.europa.eu/health/files/eudralex/vol-1/dir_2001_20/dir_2001_20_en.pdf [Last accessed 15 December 2016]
   Google Scholar
• AIFA guidelines on observational studies. Determinazione AIFA 20 Marzo 2008 Linee guida per la classificazione e conduzione degli studi osservazionali sui farmaci. Gazzetta Ufficiale della Repubblica Italiana n. 76 del 31-3-2008 Available at: http://www.omceoge.org/newsdoc/AIFA_20_3_2008.pdf [Last accessed 29 May 2017]
   Google Scholar
• Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassaemia. Blood 1997;89:739
   PubMed Web of Science ®Google Scholar
• Yaman A, Isik P, Yarali N, et al. Common complications in beta-thalassaemia patients. Int J Hematol Oncol 2013;23:3
   Google Scholar
• Majd Z, Haghpanah S, Ajami GH, et al. Serum ferritin levels correlation with heart and liver MRI and LIC in patients with transfusion-dependent thalassaemia. Iran Red Crescent Med J 2015;17:e24959
   PubMed Web of Science ®Google Scholar
• Chatterjee R, Bajoria R. Osteopenia–osteoporosis syndrome in patients with thalassaemia: understanding of type of bone disease and response to treatment. Hemoglobin 2009;33(Suppl 1):S136-S8
   PubMedGoogle Scholar
• Voskaridou E, Terpos E. Pathogenesis and management of osteoporosis in thalassaemia. Pediatr Endocrinol Rev 2008;6(Suppl 1):86-93
   PubMedGoogle Scholar
• Skordis N, Efstathiou E, Kyriakou A, Toumba M. Hormonal dysregulation and bones in thalassaemia – an overview. Pediatr Endocrinol Rev 2008;6(Suppl 1):144-8
   PubMedGoogle Scholar
• Christoforidis A, Zevgaridou E, Tsatra I, et al. Urinary iron excretion in young thalassemic patients receiving combined chelation treatment with deferoxamine and deferiprone. J Pediatr Hematol Oncol. 2007;29:598-601
   Google Scholar
• Dundar U, Kupesiz A, Ozdem S, et al. Bone metabolism and mineral density in patients with beta-thalassaemia major. Saudi Med J 2007;28:1425-9
   PubMed Web of Science ®Google Scholar
• Bisbocci D, Livorno P, Modina P, et al. Osteodystrophy in thalassaemia major. Ann Ital Med Int 1993;8:224-6
   PubMedGoogle Scholar
• Abdel-Razek AR, Magdy RI, Abdel-Salam A. Iron overload in β-thalassaemia intermedia: an emerging concern. Curr Opin Hematol 2013;20:187-92
   PubMed Web of Science ®Google Scholar
• Filosa A, Di Maio S, Aloj G, Acampora C. Longitudinal study on thyroid function in patients with thalassaemia major. J Pediatr Endocrinol Metab 2006;19:1397-403
   PubMed Web of Science ®Google Scholar
• Del Vecchio GC, Nigro A, Giordano P, De Mattia D. Management of liver disease in thalassaemia: main drug targets for a correct therapy. Curr Drug Targets 2005;5:373-8
   Google Scholar
• Elalfy MS, Adly AA, Ismail EA, et al. Therapeutic superiority and safety of combined hydroxyurea with recombinant human erythropoietin over hydroxyurea in young β-thalassaemia intermedia patients. Eur J Haematol 2013;91:522-33
   PubMed Web of Science ®Google Scholar
• Kountouras D, Tsagarakis NJ, Fatourou E, et al. Hepatic iron concentration and total body iron stores in thalassaemia major. Liver Int 2013;33:420-7
   PubMed Web of Science ®Google Scholar
• Panigrahi I, Agarwal S. Thromboembolic complications in β-thalassaemia: beyond the horizon. Thromb Res 2007;120:783-9
   PubMed Web of Science ®Google Scholar
• Yardumian A, Telfer P, Darbyshire P. Standards for the Clinical Care of Children and Adults with Thalassaemia in the UK, 2nd edn. 2008. Available at: http://www.hbpinfo.com/ukts-standards-2008.pdf [Last accessed 15 December 2016]
   Google Scholar
• Vichinsky E, Levine L. Standard-of-Care Clinical Practice Guidelines. 2012. Available at: http://thalassaemia.com/treatment-guidelines-5.aspx#gsc.tab =0 [Last accessed 10 December 2016]
   Google Scholar
• Ho PJ, Tay L, Lindeman R, et al. Australian guidelines for the assessment of iron overload and iron chelation in transfusion-dependent thalassaemia major, sickle cell disease and other congenital anaemias. Int Med J 2011;41:516-24
   Google Scholar
• Saliba AN, Harb AR, Taher AT. Iron chelation therapy in transfusion-dependent thalassaemia patients: current strategies and future directions. J Blood Med 2015;6:197-209
   PubMed Web of Science ®Google Scholar
• Pepe A, Meloni, Rossi G, et al. Cardiac and hepatic iron and ejection fraction in thalassaemia major: multicenter prospective comparison of combined deferiprone and deferoxamina therapy against deferiprone or deferoxamina monotherapy. J Cardiovasc Magnetic Resonance 2013;15:1
   PubMed Web of Science ®Google Scholar
• Piga A, Longo F, Musallam KM, et al. Assessment and management of iron overload in β-thalassaemia major patients during the 21st century: a real-life experience from the Italian WEBTHAL project. Br J Haematol 2013;161:872-83
   PubMed Web of Science ®Google Scholar
• Maggio A, Filosa A, Vitrano A, et al. Iron chelation therapy in thalassaemia major: a systematic review with meta-analyses of 1520 patients included on randomized clinical trials. Blood Cells Mol Dis 2011;47:166-75
   PubMed Web of Science ®Google Scholar
• Felisi M, Gambino A, Baiardi A, et al. Combined ICT in adolescent and adults population in Italy: results from the HTA-THAL Registry. On behalf of the HTA-THAL Registry Committee, Naples, Italian Red Cell Club, 3–4 October 2014 [Abstract]
   Google Scholar